CNTB — CONNECT BIOPHARMA HLDGS LTD
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying CNTB?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their CNTB position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Contraction regime).
- +1 tracked investor added or increased positions last quarter (Izzy Englander)
- +1 tracked investors reported holding CNTB at their latest filing
- +Macro Health is 55/100 in a Contraction regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/17/2026.
About CONNECT BIOPHARMA HLDGS LTD (CNTB)
CONNECT BIOPHARMA HLDGS LTD (CNTB) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $1M. Across recent filings, tracked investors recorded 2 new positions, 1 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CNTB
How many top investors track CNTB
Only 1 tracked investor report this position.
CNTB Ownership Composition
How CONNECT BIOPHARMA HLDGS LTD is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting CNTB
2 tracked investors have since exited this position — listed separately below.
- Izzy EnglanderJun 30, 2026Millennium ManagementShares43.7KValue$104K% Portfolio0.00%
Previously held CNTB
These investors reported CNTB in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | 112.7K | $295.2K | Mar 31, 2026 |
| Steve Cohen | Point72 Asset Management | 19.8K | $51.8K | Mar 31, 2026 |
Recent activity
- $104KAug 14, 2026
- New$46.5KFeb 17, 2026
- Increased$51.8K(19.77%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
Frequently asked questions
- How many institutional investors hold CNTB?
- 1 tracked institutional investor disclosed a position in CNTB (CONNECT BIOPHARMA HLDGS LTD) in their most recent 13F filing.
- Who is the largest institutional holder of CNTB?
- Izzy Englander, Millennium Management, holds the largest disclosed position in CNTB, valued at $1M.
- Did institutional ownership of CNTB increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 1 increased, 0 reduced, and 1 fully exited CNTB.
- Where does this CNTB ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.